Tier 2 — strong

Effects of Coenzyme Q10 Supplementation on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Yinshuang Li, Amr Ali Mohamed Abdelgawwad El-Sehrawy, Amar Shankar, Manish Srivastava, Jaafaru Sani Mohammed, Ahmed Hjazi, Mandeep Singh, I B Sapaev, Yasser Fakri Mustafa, Munther Kadhim Abosaoda
Clinical Therapeutics 2025 47(3):235-243

Bibliography

PubMed
PMID 39904656
DOI
10.1016/j.clinthera.2024.12.010
Funding
Specific funding information was not identified in the accessible PubMed record reviewed during this audit.
Competing interests
Specific competing-interest disclosures were not identified in the accessible PubMed record reviewed during this audit.

Study snapshot

DesignSystematic review and meta-analysis of randomized controlled trials
ModelAdults with type 2 diabetes receiving CoQ10 supplementation versus placebo or control.
Sample16 randomized controlled trials.
InterventionCoQ10 supplementation versus placebo/control across randomized trials; doses and durations varied.
DurationVaried across included trials; literature searched through July 2024.
EndpointsSystolic blood pressure; Diastolic blood pressure; Total cholesterol; LDL-C; HDL-C; Triglycerides; Heterogeneity

What the study showed, in plain terms

This 2025 systematic review and meta-analysis pooled randomized trials of CoQ10 in adults with type 2 diabetes. It reported statistically significant reductions in both systolic and diastolic blood pressure.

The pooled systolic reduction was about 3.86 mmHg and the diastolic reduction about 2.70 mmHg. However, heterogeneity was high for both outcomes, and a newer 2026 GRADE-assessed meta-analysis in prediabetes/type 2 diabetes did not find a significant pooled blood-pressure effect. The two syntheses therefore should be presented together rather than treating either as a final answer.

Key findings

Systolic blood pressure: WMD -3.86 mmHg (95% CI -6.01 to -1.71; P=.014), with high heterogeneity (I²=83.7%).

Diastolic blood pressure: WMD -2.70 mmHg (95% CI -4.50 to -0.91; P=.024), with very high heterogeneity (I²=92.1%).

The pooled analysis did not establish a significant improvement in the lipid profile.

What this study can and cannot tell us

Between-study heterogeneity was high for both systolic and diastolic blood-pressure outcomes.

The evidence is specific to adults with type 2 diabetes and should not be generalized to all patients with primary hypertension.

Trials varied in CoQ10 dose, formulation, treatment duration, background therapy and participant characteristics.

A newer 2026 GRADE-assessed meta-analysis in prediabetes/type 2 diabetes reached a null pooled blood-pressure conclusion, underscoring instability in the evidence base.

The review did not establish that CoQ10 reduces cardiovascular events or can replace antihypertensive therapy.

Citation network

Articles citing this research paper

3 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology